Advertisement
CUE vs VCYT
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CUE is a Buy and VCYT is a StrongBuy.
CUE's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for CUE moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 41 similar instances when the indicator left oversold territory. In 35 of the 41 cases the stock moved higher. This puts the odds of a move higher at 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 67 cases where CUE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
Following a +17.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where CUE advanced for three days, in 185 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CUE as a result. In 87 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CUE turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CUE moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CUE crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CUE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CUE entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CUE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CUE's P/B Ratio (57.612) is slightly higher than the industry average of (2.974). P/E Ratio (-0.622) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (4.143) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VCYT in upward trend: 10-day moving average broke above 50-day moving average on October 02, 2026
The 10-day moving average for VCYT crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCYT as a result. In 84 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for VCYT just turned positive on October 21, 2026. Looking at past instances where VCYT's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
VCYT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.90% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 204 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
VCYT broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. VCYT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.791) is normal, around the industry mean (65.632). P/E Ratio (33.472) is within average values for comparable stocks, (1.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 90 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
CUE | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 93 Overvalued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 90 | |
SMR RATING 1..100 | 100 | 75 | |
PRICE GROWTH RATING 1..100 | 65 | 41 | |
P/E GROWTH RATING 1..100 | 12 | 94 | |
SEASONALITY SCORE 1..100 | 46 | 47 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VCYT's Valuation (70) in the Biotechnology industry is in the same range as CUE (93). This means that VCYT’s stock grew similarly to CUE’s over the last 12 months.
VCYT's Profit vs Risk Rating (90) in the Biotechnology industry is in the same range as CUE (100). This means that VCYT’s stock grew similarly to CUE’s over the last 12 months.
VCYT's SMR Rating (75) in the Biotechnology industry is in the same range as CUE (100). This means that VCYT’s stock grew similarly to CUE’s over the last 12 months.
VCYT's Price Growth Rating (41) in the Biotechnology industry is in the same range as CUE (65). This means that VCYT’s stock grew similarly to CUE’s over the last 12 months.
CUE's P/E Growth Rating (12) in the Biotechnology industry is significantly better than the same rating for VCYT (94). This means that CUE’s stock grew significantly faster than VCYT’s over the last 12 months.
| CUE | VCYT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 85% | 1 day ago 83% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 81% |
| Advances ODDS (%) | 7 days ago 80% | 1 day ago 73% |
| Declines ODDS (%) | 1 day ago 90% | 15 days ago 79% |
| BollingerBands ODDS (%) | N/A | 1 day ago 80% |
| Aroon ODDS (%) | 1 day ago 90% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CUE’s FA Score shows that 1 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).
- CUE’s FA Score: 1 green, 4 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CUE’s TA Score shows that 3 TA indicator(s) are bullish while VCYT’s TA Score has 5 bullish TA indicator(s).
- CUE’s TA Score: 3 bullish, 6 bearish.
- VCYT’s TA Score: 5 bullish, 4 bearish.
Price Growth
CUE (@Biotechnology) experienced а +7.51% price change this week, while VCYT (@Medical Specialties) price change was +12.26% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.36%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -14.28%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.89%. For the same industry, the average monthly price growth was -6.28%, and the average quarterly price growth was +48.00%.
Reported Earning Dates
CUE is expected to report earnings on Nov 11, 2026.
VCYT is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-1.36% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Medical Specialties (+1.89% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
CUE and
Correlation & Price change
A.I.dvisor indicates that over the last year, CUE has been loosely correlated with VCYT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if CUE jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To CUE | 1D Price Change % | ||
|---|---|---|---|---|
| CUE | 100% | -0.70% | ||
| VCYT - CUE | 36% Loosely correlated | +4.32% | ||
| AXON - CUE | 33% Loosely correlated | +0.26% | ||
| AMRN - CUE | 32% Poorly correlated | -1.16% | ||
| ARRY - CUE | 31% Poorly correlated | +7.62% | ||
| PCVX - CUE | 29% Poorly correlated | +1.17% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BBP | 104.89 | 2.55 | +2.50% |
| Virtus Biotech ETF (BBP) | |||
| CMBS | 47.76 | 0.08 | +0.18% |
| iShares CMBS ETF (CMBS) | |||
| TXXI | 49.17 | 0.04 | +0.09% |
| Bondbloxx IR+M Tax-Aware Intermediate Duration ETF | |||
| PTY | 10.65 | N/A | N/A |
| PIMCO Corporate & Income Opportunity Fund | |||
| FLYD | 52.46 | -1.31 | -2.44% |
| MicroSectors Travel - 3x Inverse Leveraged ETN (FLYD) | |||